Navigation Links
Updated Overall Survival Data From Pivotal Herceptin Adjuvant,Studies in HER2-Positive Breast Cancer

ify all patients who will develop cardiac dysfunction.

Serious infusion reactions and pulmonary toxicity have occurred; rarely these have been fatal. In most cases, symptoms occurred during or within 24 hours of administration of Herceptin. Herceptin infusion should be interrupted for patients experiencing dyspnea or clinically significant hypotension. Patients should be monitored until signs and symptoms completely resolve. Discontinuation of Herceptin should be strongly considered for infusion reactions manifesting as anaphylaxis, angioedema, pneumonitis, or acute respiratory distress syndrome.

Exacerbation of chemotherapy-induced neutropenia also has occurred.

The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.

Please see full prescribing information for additional important safety information.

About Genentech

Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from, or are based on, Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.

For full prescribing information, including Boxed WARNINGS for Herceptin, please call 800-821-8590 or visit http://www.gene.com.

Contact

Genentech, Inc.
Kimberly Ocampo, 650-467-0679 (Media)
Diane Schrick, 650-225-1599 (Investors)
Sara Chenault, 206-412-7593 (Advocacy)
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
9. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
10. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
11. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
Post Your Comments:
(Date:5/15/2008)...Showed Acceptable Tolerability Profile, ... WOODCLIFF LAKE, N.J., May 15 /- The ...sylate (E7389) demonstrated activity in a,heavily ...ed or metastatic,breast cancer, according to resul...study also suggests that eribulin mesylate has a m...
(Date:5/15/2008)...ated in Blacks, Hispanics/Latinos, People ...SIPPANY, N.J., May 15 /- Daiichi Sank...he American Society of,Hypertension,s Twenty- Thir...ans demonstrated that the powerful combination dru...afely and effectively helped,patients across sever...
(Date:5/15/2008)... /- Ergonex Pharma today,announced th...(FDA) has,granted orphan drug designation to Tergu...tension (PAH). Terguride is currently being evalua..., "The FDA,s grant of orphan drug designation to ...evelopment program by offering regulatory,clinica...
(Date:5/15/2008)...or an Antiplatelet Therapy that, Combined, with As...f Plavix/Iscover and Aspirin, According to a N..., May 15 /- Decision Resources, one o...for pharmaceutical and,healthcare issues, finds th...vement in patient compared to Sanofi-Aventis/Brist...
Breaking Medicine Technology:Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 1Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 825 4Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 1Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 6032 2ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 1ABR Affinity BioReagents to Exhibit in the U S Pavilion at Medica November 14 17 2007 824 2Vioxx Settlement Announced 6028 1
..., 2007 - New data show the,investigational drug te...ted with Huntington,s disease (HD) up to 80 weeks ...ment in a 13-week trial.,These data suggest that t...educed chorea burden in long-term use., "These fin...nazine as maintenance therapy for U.S. patients wh...
...RE)--May 4, 2007 - New data from a,randomized, dou...ONE(R) (glatiramer acetate injection) along with t...um (Gd)-enhancing lesions,of the brain by 63 perce...tting multiple sclerosis (RRMS), as measured by,ma...receiving,COPAXONE(R) alone. Additionally, the nin...
Other Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:5/15/2008)..., 2008 -- The Society for Cardiovascular Angiogra...it will hold its 2009 Annual Scientific Sessions M...cused, collegial interventional cardiology meeting...ng time beginning in 2010. , The 2009 SCAI Annua...tional cardiology meeting of the spring for practi...
(Date:5/15/2008).../PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX:,WHT)...ounced that, on May,12, 2008, it had received a NA...ompany,s requests for continued listing on The NAS...ed that the Company did not provide a,definitive p...mpliance with,the continued listing requirements o...
(Date:5/15/2008).../PRNewswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq... committed to,discovering, developing and commerci...orted unaudited financial results for the second f...orted a net loss attributable,to common stockholde...quarter ended March 31, 2008, as compared to a net...
(Date:5/15/2008)...wswire-USNewswire/ -- The American Public,Health A...r overwhelmingly,passing the 2008 farm bill and ur...egislation when it arrives on his desk., Along wi... broad,support among organizations representing th...utrition interests., "While this legislation is n...
Breaking Medicine News(10 mins):Health News:SCAI announces 2009 annual scientific sessions in Las Vegas 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 2Health News:WorldHeart Announces Possible Delisting Action by NASDAQ 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
... found anti-clotting drug called bivalirudin (Angi...rapy for patients with acute coronary syndromes su...s to be less risky for patients suffering from acu... the ‘Acute Catheterization and Urgent Interventio...
...e of bird flu had been discovered in a Farm in Sou...ing authorities to cull thousands more, South Kore...While speaking in a news conference, Kim Chang-sub...rantine department said: 'This case appears quite ...
...d safety officials have banned the sale of turbot ...ents in fish //at several of Beijing’s fish market...introduced by Cao Jilin from Europe in 1992. Due ...h are fed on medicinal supplements, which sometime...
...stitute for Health Information has grouped the fiv...real and Halifax into neighbourhoods, based on fiv...ants, people living alone and lone-parent families...d housing conditions and other social issues to kn...
Other Medicine News:Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2Health News:Health Of Residents Is Affected by Various Factors 2
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig
... cross action. Round handle. Divides nucleus for p...ithout grooving. Nuclei of any hardness can be pre...er. Phaco of pre-chopped nuclear fragments is rapi...ving is diminished. Shortened ultra sound time and...
Karate chopper, spear shaped for ease of insertion into the nucleus.
Phaco chopper & iris retractor 2 mm cutting edge.
Medicine Products: